Botulinum-A toxin: an exciting new treatment option for prostatic disease.
Recently, botulinum neurotoxin type A (BoNT-A) application in the lower urinary tract has been extended to prostate disorders and we would like to review the literature on the mechanisms of action and clinical efficacy of BoNT-A treatment in the prostate. The information was gathered from MEDLINE, abstracts from recent urological meetings and from personal experience. BoNT has demonstrated promising preliminary results for male prostatic disease and translational research suggests a novel mechanism of action of BoNT in the prostate. It is important to remember that the application of BoNT in the prostate is not approved by the regulatory agencies and caution should be applied until larger randomised clinical studies are completed.
Thomas
C A
CA
Department of Urology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Guercini
F
F
Chuang
Y-C
YC
Chancellor
M B
MB
D000970:Antineoplastic Agents / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011469:Prostatic Diseases / Q000188:drug therapy*; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011472:Prostatitis / Q000188:drug therapy
D000970:Antineoplastic Agents; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A